Insulin-dependent diabetes may occur in patients with cancers who are treated with
checkpoint inhibitors (CPIs). We reviewed cases occurring over a 6-year period at two …

Within tumors, some areas are less oxygenated than others. Since their home ground is
under chronic hypoxia, tumor cells adapt to this condition by activating aerobic glycolysis; …

The recent success of immunotherapies has highlighted the power of leveraging the
immune system in the fight against cancer. In order for most immune‐based therapies to …

Synthetic mRNA represents an exciting cancer vaccine technology for the implementation of
effective cancer immunotherapy. However, inefficient in vivo mRNA delivery along with a …

Background No study has evaluated the predictive and prognostic role of CD8 and PD-L1
coexpression in non–small-cell lung cancer (NSCLC). Methods We analyzed RNA …

Photothermal therapy (PTT) is a promising cancer treatment, but it has so far proven
successful only with relatively small subcutaneous tumors in animal models. Treating larger …

To assess the association of the programmed cell death ligand 1 (PD‐L1) with cisplatin‐
based neo‐adjuvant chemotherapy (NAC) response, we investigated the level of PD‐L1 and …

The ability of cancer cells to evade the immune system is one of the most deadly
characteristics of the majority of malignant tumours. Accordingly, the recent development of …

Cancer is a heterogeneous disease with unique genomic and phenotypic features that differ
between individual patients and even among individual tumor regions. In recent years, large …

Checkpoint inhibitors (CPIs) targeting programmed death 1 (PD-1)/programmed death
ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) have revolutionized cancer …